Anzeige
Mehr »
Mittwoch, 29.10.2025 - Börsentäglich über 12.000 News
Die 80-Milliarden-Dollar-Nuklear-Renaissance: Warum Uran der heißeste Sektor der Welt ist
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40P83 | ISIN: CH1384053976 | Ticker-Symbol:
NASDAQ
29.10.25 | 15:35
0,840 US-Dollar
-18,45 % -0,190
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
NLS PHARMACEUTICS LTD Chart 1 Jahr
5-Tage-Chart
NLS PHARMACEUTICS LTD 5-Tage-Chart

Aktuelle News zur NLS PHARMACEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13:00NLS Pharmaceutics Ltd.; Kadimastem Ltd.: NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger41ZURICH, Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS" or the "Company"), a biopharmaceutical company focused on developing innovative therapies for central...
► Artikel lesen
12:00NLS Pharmaceutics Ltd.; Kadimastem Ltd.: NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem46ZURICH, Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company...
► Artikel lesen
NLS PHARMACEUTICS Aktie jetzt für 0€ handeln
11:30NLS Pharmaceutics to execute 1-for-10 reverse share split1
09:53NLS Pharmaceutics Ltd.; Kadimastem Ltd.: NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares53ZURICH and NESS ZIONA, Israel, Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company") and Kadimastem Ltd. (TASE: KDST) ("Kadimastem")...
► Artikel lesen
MoNLS Pharmaceutics Ltd.; Kadimastem Ltd.: NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies238The collaboration will progress under the combined company, NewCelX, upon completion of the anticipated merger ZURICH and NESS ZIONA, Israel, Oct. 27, 2025 /PRNewswire/ -- NLS Pharmaceutics...
► Artikel lesen
DoNLS Pharmaceutics and Kadimastem merger to close Oct. 30 after Nasdaq approval2
DoNLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer2
DoNLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 20251.809ZURICH, Oct. 23, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system...
► Artikel lesen
10.10.Fusion mit Kadimastem: NLS Pharmaceutics reicht Finanzberichte ein1
10.10.NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer-
30.09.NLS Pharmaceutics stock tumbles after merger approval with Kadimastem3
30.09.NLS Pharmaceutics: Aktie bricht nach Fusionszustimmung mit Kadimastem ein1
30.09.Aktionäre von NLS Pharmaceutics stimmen Fusion mit Kadimastem zu2
30.09.NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer2
30.09.NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting465Vote clears final corporate milestone, paving the way for the closing of the merger and the combined company of NewCelX Ltd., a Nasdaq-listed biotechnology company ZURICH, Sept. 30, 2025 /PRNewswire/...
► Artikel lesen
25.09.NLS Pharmaceutics files to sell 5M common shares for holders2
25.09.NLS Pharmaceutics Ltd. - F-1, Registration statement for certain foreign private issuers2
19.09.NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer1
10.09.Fusion von NLS Pharmaceutics und Kadimastem: SEC erteilt Freigabe4
10.09.SEC clears registration for NLS Pharmaceutics and Kadimastem merger1
Weiter >>
47 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1